The socioeconomic impact of Alzheimer's disease

International Journal of Geriatric Psychiatry

Volumn 16, Issue 3, 2001, Pages 249-253

  Bosanquet, Nick ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; PSYCHOTROPIC AGENT;

ALZHEIMER DISEASE; CAREGIVER; CLINICAL TRIAL; DEMENTIA; DRUG COST; EDITORIAL; FINANCIAL MANAGEMENT; GOVERNMENT; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEALTH SERVICE; HOME CARE; HUMAN; MENTAL DISEASE; PATIENT CARE; POPULATION RESEARCH; SOCIAL PROBLEM; SOCIOECONOMICS; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CAREGIVERS; COST CONTROL; COST OF ILLNESS; DRUG COSTS; GREAT BRITAIN; HEALTH CARE COSTS; HEALTH PLANNING; HEALTH SERVICES ACCESSIBILITY; HOME NURSING; HUMANS; MIDDLE AGED; SOCIOECONOMIC FACTORS;

EID: 0035070691     PISSN: 08856230     EISSN: None     Source Type: Journal    
DOI: 10.1002/gps.332     Document Type: Editorial

References (41)

1. Practice guidelines for the treatment of patients with Alzheimer's disease and other dementias of late life
2. Chronic stress in caregivers of dementia patients is associated with reduced lymphocyte sensitivity to glucocorticoids
3. The health of persons giving care to the demented elderly: A critical review of the literature
4. Donepezil for mild and moderate Alzheimer's disease
5. Alzheimer's and managers - Breaking the communication block
6. Developing an investment approach to programmes for Alzheimer's disease patients
7. Alzheimer's disease. An international perspective on care delivery
8. Time until institutionalization and death in patients with dementia
9. The effects of donepezil in Alzheimer's disease - Results from a multinational trial
10. Psychotropic drug use among caregivers of patients with dementia
11. Cholinesterase inhibitors: A new class of psychotropic compounds
12. The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease
13. Drug costs in dementia care
14. Epidemiology
15. Alzheimer's disease: The burden of illness in England
16. The family caregiver's role in Alzheimer's disease
17. Managing Alzheimer's disease: The cost of care per patient
18. The cost-effectiveness of donepezil in Swedish patients with Alzheimer's disease: Markov Model
19. Methodological issues in health economic studies of dementia
20. Spousal caregivers of dementia victims: Longitudinal changes in immunity and health
21. Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality
22. Alzheimer's disease: The unpaid burden of caring
23. New drug treatment for Alzheimer's disease: Lessons for healthcare policy
24. A family intervention to delay nursing home placement of patients with Alzheimer's disease: A randomized control trial
25. The health impact of living with a cognitively impaired elderly spouse: Depressive symptoms and social functioning
26. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease
27. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada
28. Incontinence and troublesome behaviors predict institutionalization in dementia
29. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group
30. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial
31. Dealing with Alzheimer's disease: Caregiver issues
32. An economic evaluation of donepezil in the treatment of Alzheimer's disease
33. Pharmacotherapy for people with Alzheimer's disease: A Markov-cycle evaluation of five years therapy using donepezil
34. Europe should give Alzheimer's disease higher priority
35. Distress and burden for family caregivers
36. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: Result of a one-year, double-blind, randomised trial
37. Harmonization of availability of drugs for Alzheimer's disease
38. Donepezil enhances global function, cognition, and activities of daily living compared with placebo in a one year, double-blind trial in patients with mild to moderate Alzheimer's disease